Last reviewed · How we verify

NCT05603767

Effects of Receptive Music Therapy Combined With Virtual Reality on Prevalent Symptoms in Patients With Advanced Cancer

Status unknown NA Last updated 3 November 2022
What this trial tests

NA trial testing RMT+ VR in Music Therapy in 60 participants. Status unknown.

Timeline
19 September 2022
Primary endpoint
11 October 2022
11 October 2023

Quick facts

Lead sponsorAustral University, Argentina
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment60
Start date19 September 2022
Primary completion11 October 2022
Estimated completion11 October 2023
Sites1 location across Argentina

Drugs / interventions tested

Conditions studied

Sponsor

Austral University, Argentina

Who can join

18 and older, any sex, with Music Therapy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The present research seeks to determine whether a single responsive music therapy intervention combined with virtual reality (RMT+VR) reduces prevalent symptoms and improves their overall well-being in hospitalized adult patients with advanced oncologic disease receiving palliative care. This is a prospective study of a randomized clinical trial with a control group. The main variables are pain, exhaustion, drowsiness, nausea, loss of appetite, dyspnea, depression, anxiety, sleep and well-being as well as heart rate.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Music Therapy

Currently open trials in the same condition.

Other Austral University, Argentina trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05603767.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing